We are live on
!
Find out more
MU
Mirova US Portfolio holdings
AUM
$8.81B
1-Year Est. Return
21.38%
This Fund
S&P 500
This Quarter
Est. Return
-6.92%
1 Year Est. Return
+21.38%
3 Year Est. Return
+80.7%
5 Year Est. Return
+106.85%
10 Year Est. Return
–
AUM
$4.28B
AUM Growth
-$363M
(-7.8%)
Cap. Flow
+$28.7M
Cap. Flow
% of AUM
0.67%
Top 10 Holdings %
Top 10 Hldgs %
62.29%
Holding
30
New
2
Increased
–
Reduced
27
Closed
1
Top Buys
| 1 |
Edwards Lifesciences
EW
|
+$75.4M |
| 2 |
Deere & Co
DE
|
+$73.7M |
Top Sells
| 1 |
Danaher
DHR
|
+$87.7M |
| 2 |
TSMC
TSM
|
+$4.33M |
| 3 |
Thermo Fisher Scientific
TMO
|
+$3.32M |
| 4 |
Mercado Libre
MELI
|
+$3.31M |
| 5 |
Sunrun
RUN
|
+$3.18M |
Sector Composition
| 1 | Technology | 25.75% |
| 2 | Healthcare | 22.82% |
| 3 | Financials | 16.06% |
| 4 | Consumer Discretionary | 11.79% |
| 5 | Utilities | 6.99% |
Similar funds
MERSOM
CFB
MOACM
SWP
CB
WT
OAM
PEA
Mirova US's Q3 2022 Portfolio in Review
As of Q3 2022, Mirova US held 30 positions worth $4.28B, down 7.8% from $4.64B the previous quarter. Its ten largest holdings account for 62% of the portfolio.
Mirova US's Q3 2022 filing shows 2 new, 27 reduced and 1 closed positions. Its largest new stake was Edwards Lifesciences: 783,459 shares worth $64.7M. The largest sale was Danaher, an estimated $87.7M.
By sector, the portfolio is most concentrated in Technology at 26% of assets, down from 27% a quarter earlier, followed by Healthcare and Financials.
- Mirova US's largest Q3 2022 buy was Edwards Lifesciences: 783,459 shares worth $64.7M.
- Mirova US's biggest Q3 2022 reduction was Danaher, cutting an estimated $87.7M.
- Mirova US fully exited Colgate-Palmolive in Q3 2022, selling an estimated $207K.
- Mirova US's ten largest holdings make up 62% of its $4.28B portfolio in Q3 2022.
- Mirova US opened 2 new positions and closed 1 in Q3 2022.
- Mirova US's portfolio value fell 7.8% quarter-over-quarter to $4.28B.
Based on Mirova US's 13F filing for Q3 2022, filed 3 Nov 2022.